Weight Loss•Evidence reviewed August 2026•11 min read

GLP-1 Weight Loss Plateau: Why It Happens and What to Do When the Scale Stalls

Weight loss slows or stalls on Ozempic, Wegovy, Mounjaro, or Zepbound for most people. Understand the physiology of the plateau, when it is a normal deceleration, and what adjustments are worth discussing with your prescriber.

Written by OffRamp GLP-1 Editorial TeamReviewed by OffRamp GLP-1 Research Team

A slowing scale is not always a failing treatment

Weight loss on GLP-1 therapy follows a curve, not a straight line. A plateau can reflect metabolic adaptation, a smaller energy gap, behavioral drift, or the body reaching a new equilibrium, but it can also signal a correctable intake or dosing problem.

Searches such as “GLP-1 weight loss plateau,” “Wegovy stopped working,” and “why am I not losing weight on Ozempic” all point to the same experience: the scale that had been moving week after week slows down or stops. This moment is frustrating and often prompts people to make their own changes—skipping doses, slashing calories, or adding unprescribed supplements—before understanding what the plateau actually means.

The STEP and SURMOUNT trials show that weight loss on these medications typically follows a curve: rapid early loss, a gradual deceleration, and a plateau or near-plateau that begins between weeks 48 and 72. That is not evidence that the medication failed. It is evidence that the body is responding to a lower body weight with the same metabolic adjustments that occur after any substantial weight loss, including a smaller energy deficit, a lower resting metabolic rate, and hormonal changes that defend the new weight.

Key highlights

  • •A plateau on a GLP-1 does not automatically mean the medication stopped working.
  • •Weight loss curves from STEP and SURMOUNT show deceleration beginning around weeks 48–72 for most people.
  • •Metabolic adaptation, a narrowing energy gap, and behavioral drift are the three most common contributors.
  • •Dose skipping, severe calorie restriction, or relying on random supplements are not evidence-based solutions.

What the weight loss curve actually looks like on GLP-1s

In the STEP 1 trial of once-weekly semaglutide 2.4 mg, mean body weight fell steeply through roughly week 28, then continued a slower decline through week 60, and began to plateau around week 68. By week 68 the average participant had lost about 14.9% of baseline body weight. After that point the curve flattened substantially even though treatment continued. In the extension that continued through week 120, participants who stayed on semaglutide maintained most of the weight loss without additional decline.

The SURMOUNT trials with tirzepatide showed a similar shape: rapid loss in the first 24 weeks, continued but slower loss through week 72, then a plateau or gradual uptick in some groups. The pattern is not unique to GLP-1 drugs. Nearly every effective obesity intervention produces a weight-loss curve that decelerates over time because the metabolic and behavioral forces that resist further weight change grow stronger as body weight drops.

Three common reasons the scale stalls

The first and most physiological reason is metabolic adaptation. When body weight decreases, resting energy expenditure also decreases—partly because there is simply less tissue to maintain, and partly because the body adjusts hormone signals (including leptin, ghrelin, and thyroid axes) to conserve energy. A person who was losing weight on 1,800 calories at 220 pounds may need fewer calories to maintain weight at 180 pounds. That does not mean the medication stopped working; it means the energy gap narrowed.

The second reason is behavioral drift. Appetite suppression from GLP-1 therapy, although usually sustained, can change over time. Some people find that the initial strong reduction in appetite becomes more moderate after several months, leading to slightly larger portions, more snacks, or less careful food choices without consciously deciding to change anything. A 2026 randomized trial found that adults on semaglutide 2.4 mg still consumed roughly 240 to 292 fewer calories per laboratory meal than placebo at weeks 20, 40, and 60, but the gap between groups was not identical at every time point. Even small daily intake increases can turn a calorie deficit into maintenance.

The third reason is that the initial rapid loss was partly fluid and glycogen, not just fat. Early-week weight loss on any calorie-restricted plan includes water and carbohydrate stores. Once those initial losses are complete, the rate of fat loss is slower and steadier. A plateau that lasts two to three weeks may not reflect stalled fat loss at all—it may simply be the transition from early rapid loss to the true fat-loss rate.

How to tell a real plateau from a natural slowdown

A useful working definition is that a plateau means no downward trend in body weight for four weeks or more despite continued treatment and consistent eating and activity patterns. A one- or two-week pause, especially after a period of rapid loss, is often just the body catching up. Hormonal fluctuations, fluid shifts, changes in bowel habits, and sodium or carbohydrate intake changes can mask fat loss on the scale for one to two weeks without meaning that fat loss stopped.

Tracking weight weekly under the same conditions—same day, same time, after the same morning routine—reduces noise. Pay more attention to the four-week trend than to week-to-week changes. If the four-week average is flat or slightly up, and this persists through a second four-week window, it is worth a conversation with the prescriber. Meanwhile, strength, energy, clothing fit, and appetite changes provide context that a scale alone cannot.

What not to do when the scale stalls

Do not skip, stretch, split, or reduce a prescribed dose to “restart” weight loss. Some people on online forums describe spacing injections or halving doses to extend coverage, but those practices have not been studied for safety or efficacy, and they may waste the medication’s therapeutic window without producing additional loss.

Do not slash calorie intake to the lowest possible level. A severely restricted diet can accelerate muscle loss, increase fatigue, lower metabolic rate further, and reduce the very energy and nutrient intake needed to preserve strength and function. The goal during a plateau is not to out-restrict the body; it is to check whether current intake, protein, hydration, and activity still support a reasonable deficit.

Do not add over-the-counter weight-loss supplements, herbal products, or unprescribed medications. No supplement has been shown in rigorous GLP-1-specific research to break a plateau safely, and some interact with diabetes medications, blood pressure, or kidney function. If a plateau persists despite good intake habits and consistent dosing, the answer is a clinician-guided review, not a supplement stack.

What to review instead: a practical plateau checklist

First, review intake honestly for three representative days. Has the calorie deficit narrowed? Are portions creeping up? Did a snack habit return that had stopped in the first months? Are meals still centered on protein and vegetables, or has variety shrunk while calories stayed the same? A 2026 EASO, EFAD, and ECPO consensus statement recommends proactive nutrition assessment during incretin-based therapy rather than assuming current intake is still adequate for weight loss.

Second, check protein and resistance training. Preservation of lean mass helps support resting metabolic rate. If protein intake has slipped or training frequency dropped, muscle support may be a contributing factor. The SURMOUNT-1 body-composition substudy found that roughly one-quarter of tirzepatide-associated weight loss was lean mass. Preserving the remaining lean tissue supports both metabolic rate and long-term function.

Third, review fluid intake, sleep, and stress. Dehydration, poor sleep, and sustained stress can shift hormone signals in ways that blunt weight loss. These are not the main cause of a GLP-1 plateau in most people, but they are worth correcting before assuming the medication needs a change.

Fourth, confirm that the plateau is not actually weight maintenance at a healthy lower weight. If body weight is already in a healthier range, the natural slowing of loss may be the body finding a new stable point. The medical question shifts from “how do I lose more” to “can I sustain this weight with tolerable medication support and good nutrition.”

When to talk to your prescriber about a plateau

If weight loss has been flat or trending upward for four to eight weeks despite consistent dosing, stable eating, and normal tolerance, a clinician review is reasonable. The conversation should include medication dose and duration, current weight and trend, any dose changes, gastrointestinal symptoms, intake quality, protein, training, and whether any new medical issues or medications could be contributing.

A prescriber may consider dose adjustment where permitted by the prescribing label, or may review whether an alternative medication is appropriate. Dose increases are not always the answer—especially if the current dose was reached recently or if gastrointestinal symptoms are still present. The prescriber may also check thyroid function, blood pressure, kidney function, glucose, or other labs if a plateau coincides with fatigue, weakness, or other symptoms.

Do not approach the appointment as a demand for a higher dose. Bring the weight trend, the plateau duration, and the other variables checked above. The goal is shared decision-making based on evidence, not an escalation arms race.

When a plateau is actually maintenance

A significant portion of people who reach a stable lower weight on GLP-1 therapy will not continue losing indefinitely. That is not failure. The STEP 1 extension showed that participants who stayed on semaglutide maintained most of their weight loss through week 120 without additional decline, which is a clinically meaningful result even without further loss.

The SURMOUNT-4 trial reinforced that continued treatment helps maintain weight reduction, while switching to placebo produced substantial regain. If a plateau represents a stable, healthier weight with tolerable side effects and good nutrition, the next discussion with the prescriber is about the right maintenance dose—not about forcing more loss.

Frequently asked questions

Why did my weight loss slow down on Ozempic, Wegovy, Mounjaro, or Zepbound?

Weight loss on GLP-1 therapy follows a decelerating curve, not a straight line. As body weight drops, the energy deficit narrows, resting metabolic rate decreases, and hormonal signals adjust to conserve energy. Behavioral drift—subtle increases in portion size or snack frequency—can also narrow the deficit. A slowdown is not automatically a treatment failure.

How long does a GLP-1 weight loss plateau usually last?

There is no fixed duration. A plateau may last several weeks and then resolve on its own as habits adjust or the body reaches a new equilibrium. A plateau that continues for four to eight weeks without any downward trend is worth reviewing with the prescriber.

Should I skip doses or lower my GLP-1 dose to break a plateau?

No. Skipping, stretching, splitting, or reducing a prescribed dose has not been studied for safety or efficacy and may waste the therapeutic window. Dose decisions belong with the prescribing clinician.

Should I eat less to break a GLP-1 plateau?

Severely restricting calories during a plateau can accelerate muscle loss, lower metabolic rate further, and increase fatigue. Instead of eating less, check whether current intake, protein distribution, fluid, and activity still support a reasonable deficit. A comprehensive nutrition review is more useful than guessing at a lower calorie number.

Can a GLP-1 weight loss plateau mean the medication stopped working?

Not necessarily. The STEP 1 extension showed that semaglutide maintained weight loss through 120 weeks without further decline, and SURMOUNT-4 showed that continued tirzepatide maintains weight reduction better than placebo. A plateau can mean the body has reached a new equilibrium at a lower weight, which is still a successful treatment outcome.

When should I call my doctor about a weight loss plateau on a GLP-1?

If weight loss has been flat or trending upward for four to eight weeks despite consistent dosing, stable eating, and normal tolerance, schedule a clinician review. The prescriber can assess dose appropriateness, medication timing, and other possible contributors such as thyroid function or concurrent medical conditions.

Sources

This guide draws on weight-loss trajectory data from the STEP 1 trial, SURMOUNT-4 withdrawal trial, SURMOUNT-1 body-composition analysis, 2026 semaglutide energy-intake trial data, and 2026 EASO/EFAD/ECPO consensus guidance on incretin-based therapy nutrition. A plateau has multiple possible causes, and this guide cannot replace a clinician-supervised medication review.

A slowing scale is not always a failing treatment

Weight loss on GLP-1 therapy follows a curve, not a straight line. A plateau can reflect metabolic adaptation, a smaller energy gap, behavioral drift, or the body reaching a new equilibrium, but it can also signal a correctable intake or dosing problem.

Track weight, food, and symptoms free →
This page is for general education only. It is not medical advice and should not replace care from your licensed healthcare provider.